Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 8 of 14

7. Sana Biotechnology Inc (NASDAQ:SANA)

Number of Hedge Fund Holders In Q4 2024: 24

Sana Biotechnology Inc (NASDAQ:SANA) is a biotech company that makes engineered cells as medicines. It is making therapies for conditions including type 1 diabetes, autoimmune diseases, and cancer.

The stock is up significantly so far in 2025 as it announced positive clinical results from its type 1 diabetes study. The company reported the successful transplantation of UP421, which is an allogeneic primary islet cell treatment using their hypoimmune technology in a type 1 diabetes patient without requiring immunosuppressive drugs.

This caused the stock to skyrocket.

The consensus price target of $14.25 implies 450.19% upside.

SANA is up 58.90% year-to-date.

Page 8 of 14